AEMD (Aethlon Medical) 5-Year EBITDA Growth Rate: 51.50% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AEMD Aethlon Medical Inc AEMD
19 GF Score
Price $1.83
! 2 Warning Signs
View Full Analysis

What is Aethlon Medical 5-Year EBITDA Growth Rate?

Aethlon Medical AEMD +0.55% 19 5-Year EBITDA Growth Rate is 51.50% as of Jun. 2026. GuruFocus rates AEMD with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Aethlon Medical's EBITDA per Share for the three months ended in Jun. 2026 was $-3.91.

During the past 3 years, the average EBITDA Per Share Growth Rate was 72.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 51.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aethlon Medical was 72.10% per year. The lowest was 7.90% per year. And the median was 27.40% per year.

Aethlon Medical  (NAS:AEMD) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Aethlon Medical 5-Year EBITDA Growth Rate Related Terms

AEMD vs PFSA, LUDG, NUMD: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Aethlon Medical's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aethlon Medical 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Aethlon Medical's 5-Year EBITDA Growth Rate falls into.


AEMD
19GF Score
Aethlon Medical Inc AEMD
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aethlon Medical 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 51.50% mean?
Aethlon Medical (AEMD) has a 5-Year EBITDA Growth Rate of 51.50% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Aethlon Medical and its competitors.
Is Aethlon Medical's 5-Year EBITDA Growth Rate too high?
Aethlon Medical's current 5-Year EBITDA Growth Rate is 51.50%. Overall, Aethlon Medical has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's 5-Year EBITDA Growth Rate compare to PFSA and LUDG?
Aethlon Medical's 5-Year EBITDA Growth Rate of 51.50% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Aethlon Medical and its competitors. Aethlon Medical's current 5-Year EBITDA Growth Rate is 51.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current 5-Year EBITDA Growth Rate of 51.50%. The current 5-Year EBITDA Growth Rate is 51.50%. Aethlon Medical's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current 5-Year EBITDA Growth Rate is 51.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aethlon Medical Business Description

Address 11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
19GF Score

Get the complete analysis for AEMD

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.83
Price